OpenAI acquires Orchestra Bio

OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, aiming to help biopharma teams speed up drug development. The deal amount was not disclosed.

• OpenAI Works with Distribution Partners on Consistent Safeguards2026-10-21
• OpenAI outlines blueprint to empower cyber defenders2026-10-21
• Harvard mathematicians split over OpenAI math breakthrough2026-10-21
• AT&T rethinks in-house legal work with OpenAI2026-10-21
• Trail of Bits launches AI agent patching and regression plugins2026-10-21